for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DAIICHI SANKYO COMPANY, LIMITED

4568.T

Latest Trade

3,701.00JPY

Change

58.00(+1.59%)

Volume

4,254,400

Today's Range

3,688.00

 - 

3,799.00

52 Week Range

1,731.00

 - 

3,799.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,643.00
Open
3,699.00
Volume
4,254,400
3M AVG Volume
64.03
Today's High
3,799.00
Today's Low
3,688.00
52 Week High
3,799.00
52 Week Low
1,731.00
Shares Out (MIL)
1,944.96
Market Cap (MIL)
7,748,785.00
Forward P/E
109.53
Dividend (Yield %)
0.69

Next Event

Q3 2021 Daiichi Sankyo Co Ltd Earnings Release

Latest Developments

More

Daiichi Sankyo: To Buy Back Up To 3.1% Worth Of Outstanding Stock Worth 100 Bln Yen

BioInvent Gets EUR 2 Mln Milestone Payment From Daiichi Sankyo

Seagen Says On Oct 19 Co Filed Complaint In Court Against Daiichi Sankyo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DAIICHI SANKYO COMPANY, LIMITED

Daiichi Sankyo Co Ltd is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Industry

Biotechnology & Drugs

Contact Info

Daiichi Sankyo Bldg. A/B Kan

3-5-1, Nihombashi Hon-cho

CHUO-KU, TKY

103-8426

Japan

+81.3.62251111

https://www.daiichisankyo.co.jp/

Executive Leadership

Sunao Manabe

Executive President, President, Chief Executive Officer, Representative Director

Toshiaki Sai

Chief Financial Officer, Executive Vice President, Vice President, Chief Director of Business Strategy, Representative Director

Kentaro Takamura

Managing Executive Officer, Director of Finance & Accounting in Main Business Strategy Unit

Satoru Kimura

Senior Managing Executive Officer, Chief Director of Pharmaceutical Sales, Director

Shoji Hirashima

Senior Managing Executive Officer, Chief Director of Product Strategy, Director

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2018

1.0K

2019

0.9K

2020

1.0K

2021(E)

1.0K
EPS (JPY)

2018

30.437

2019

48.067

2020

66.403

2021(E)

31.036
Price To Earnings (TTM)
61.01
Price To Sales (TTM)
7.89
Price To Book (MRQ)
5.32
Price To Cash Flow (TTM)
45.35
Total Debt To Equity (MRQ)
13.80
LT Debt To Equity (MRQ)
12.27
Return on Investment (TTM)
6.65
Return on Equity (TTM)
5.64

Latest News

Latest News

Daiichi Sankyo's COVID-19 vaccine selected by Japanese drug discovery body

Daiichi Sankyo Co said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.

AstraZeneca to pay up to $6 bln in new cancer drug deal with Daiichi

British drugmaker AstraZeneca could pay up to $6 billion to Japan's Daiichi Sankyo as part of a new collaboration to develop and market a type of potential cancer treatment for multiple tumour types.

Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine now being developed by AstraZeneca Plc and the University of Oxford for use in Japan.

Daiichi Sankyo in talks with AstraZeneca on virus vaccine supply in Japan

Daiichi Sankyo Co is in discussions with AstraZeneca Plc on developing supplies of a vaccine for the coronavirus in Japan, the Japanese company said on Friday.

BRIEF-Thermo Fisher, Daiichi Sankyo To Co-Develop Global Companion Diagnostic For Non-Small Cell Lung Cancer

* THERMO FISHER SCIENTIFIC AND DAIICHI SANKYO TO CO-DEVELOP GLOBAL COMPANION DIAGNOSTIC FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER

BRIEF-Daiichi Sankyo And Syneos Health Form Strategic Coalition For Development Of Daiichi Sankyo’S Adc Oncology Pipeline

* DAIICHI SANKYO AND SYNEOS HEALTH® FORM STRATEGIC COALITION FOR DEVELOPMENT OF DAIICHI SANKYO’S ADC ONCOLOGY PIPELINE

BRIEF-Daiichi Sankyo Initiates Clinical Trial With In Collaboration With Sarah Cannon Research Institute

* DAIICHI SANKYO INITIATES CLINICAL TRIAL WITH 5TH DXD ADC, DS-6157, IN COLLABORATION WITH SARAH CANNON RESEARCH INSTITUTE Source text for Eikon: Further company coverage:

BRIEF-Daiichi Sankyo Submits Supplemental New Drug Application For Trastuzumab Deruxtecan In Japan For Treatment Of Patients With HER2 Positive Metastatic Gastric Cancer

* DAIICHI SANKYO SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION FOR TRASTUZUMAB DERUXTECAN IN JAPAN FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC GASTRIC CANCER

BRIEF-Daiichi Sankyo Co Ltd - Announces 3-For-1 Share Split On Sept. 30

* DAIICHI SANKYO CO LTD - ANNOUNCES 3-FOR-1 SHARE SPLIT ON SEPT. 30 Source text for Eikon: Further company coverage:

BRIEF-Ultragenyx Pharmaceutical Says Daiichi Sankyo Granted Non-Exclusive License To Ultragenyx Hela Manufacturing Platform

* DAIICHI SANKYO GRANTED NON-EXCLUSIVE LICENSE TO ULTRAGENYX HELA MANUFACTURING PLATFORM

AstraZeneca, Daiichi's breast cancer drug gets accelerated approval from FDA

(This Dec.20 story corrects first paragraph to say the approval came four months ahead of schedule, not three months, after FDA clarification)

AstraZeneca-Daiichi drug halts cancer for months in first readout

An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration (FDA) on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor usually affecting joints and limbs.

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up